Please login to the form below

Not currently logged in

Atlantis Webinar

The development of new therapeutic agents is set to revolutionise treatment of hepatitis C. These new therapies represent a real transformation in care; offering fewer, milder side effects, a shorter treatment duration and dramatically improved success rates. However, they are expensive and there is a possibility that the virus could become resistant if adherence is sub-optimal. This raises fresh questions around medical funding and the types of support patients will need in order to get the best results from their treatments.

For this webinar we brought together a panel of experts in hepatitis C to discuss this important topic, including a healthcare funder, a pharma medical director and an adherence researcher. They discuss the most important issues and examine the opportunities these new treatments present patients and the wider healthcare community.

Speaker Biographies:

Steve Miller, MDSteve Miller, MD
Senior Vice President & Chief Medical Officer, ExpressScripts
United States

Dr. Steve Miller's focus is on supporting government relations, leading the Pharmacy & Therapeutics committee, managing the Medical Affairs team and interfacing with client groups. Steve has served as Chief Medical Officer since 2006 and has been a valuable leader in all clinical matters, including our e-prescribing initiatives, our specialty offering and overall product development. He received his medical degree from the University of Missouri-Kansas City, and he trained in the Pathology and Research fellowship at the University of Alabama at Birmingham and in cardiology at the University of California, San Francisco. Steve also earned his MBA at the Olin School of Business at Washington University in St. Louis. 


Dr Christina JacksonDr Christina Jackson
Senior Health Psychology Specialist, Atlantis Healthcare 
United Kingdom
Christina’s academic research has focused on adherence issues. Her doctoral thesis involved development of a measure of factors associated with non-adherence, and creation of an online intervention that successfully reduced concerns about medicines (School of Pharmacy, University of London).  Previously, Christina worked on adherence-related projects at the Centre for Behavioural Medicine (School of Pharmacy). Christina’s research interests are in adherence, online methodologies, development of measures, intervention development and evaluation.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...